Workflow
国药一致(000028.SZ)上半年归母净利润6.66亿元 同比下降10.43%
Sinopharm AccordSinopharm Accord(SZ:000028) 智通财经网·2025-08-14 09:49

Core Viewpoint - The company reported a decline in both revenue and net profit for the first half of 2025, primarily due to industry policy changes and intensified market competition [1] Revenue Summary - The company achieved a total revenue of 36.797 billion yuan, representing a year-on-year decrease of 2.62% [1] - The distribution segment generated revenue of 26.783 billion yuan, down 1.09% year-on-year [1] - The retail segment, represented by Guoda Pharmacy, reported revenue of 10.479 billion yuan, a decline of 6.46% year-on-year [1] Profit Summary - The net profit attributable to shareholders was 666 million yuan, reflecting a year-on-year decrease of 10.43% [1] - The distribution segment's net profit was 482 million yuan, down 7.82% year-on-year [1] - Guoda Pharmacy achieved a net profit of 17 million yuan, showing a significant increase of 215.81% year-on-year [1] Factors Influencing Performance - The decline in the distribution segment's revenue was influenced by changes in industry policies and increased market competition [1] - Delays in customer payments led to an increase in long-term accounts receivable, resulting in higher provisions for bad debts and contributing to the profit decline [1] - Guoda Pharmacy's revenue decrease was attributed to market conditions, competitive landscape, and strategic store closures, while its profit growth was driven by optimization of procurement systems and business structure [1]